Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis Biogen Idec, 16 Jun 2014 Accessed on 19 Jun 2014 from http://www.biogenidec.com/press_release_details.aspx?ID=14712&Action=1&NewsId=2358&M=NewsV2&PID=61997. CommentRecommendBookmarkWatch